# Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Canonical URL: https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference
Ticker: ELVN
Company: Enliven Therapeutics
Source: Enliven Therapeutics
Published: 2026-02-25 21:05 EST
Original Source URL: https://ir.enliventherapeutics.com
## Summary

BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat

## Article Body
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat
## Recent Company News
- 2026-06-03 20:05 EST — [Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-host-webcast-conference-call-to-discuss-phase-1-elvn-001-clinical-data-being-presented-at-eha-2026-congress) — Source: Enliven Therapeutics
- 2026-05-21 20:05 EST — [Enliven Therapeutics to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-to-present-at-upcoming-investor-conferences) — Source: Enliven Therapeutics
- 2026-05-12 13:53 EST — [Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-announces-oral-presentation-at-the-eha-2026-congress-featuring-additional-positive-phase-1-clinical-trial-data-for-elvn-001-in-cml) — Source: Enliven Therapeutics
- 2026-05-07 20:05 EST — [Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-a-business-update) — Source: Enliven Therapeutics
- 2026-03-03 21:05 EST — [Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/ELVN/enliven-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update) — Source: Enliven Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)